Cumberland Pharmaceuticals had been responsible for marketing Ethyol and Totect in the US, but Clinigen is to take back control of them as part of plans to grow its presence in the higher-value US market
More From BioPortfolio on "Clinigen takes back direct control of two of its oncology drugs in the US"